Market Place
Sourcing Support
Bristol Myers Presents Long-term EMERGENT Data in Schizophrenia
31 Oct 2024 //
BUSINESSWIRE
Bristol Myers Squibb to Present Data at Psych Congress 2024
28 Oct 2024 //
BUSINESSWIRE
BMS` schizophrenia gem Cobenfy was salvaged from the scrapheap
07 Oct 2024 //
FIERCE PHARMA
Segal Trials Key In FDA Approval Of Cobenfy For Schizophrenia
04 Oct 2024 //
BUSINESSWIRE
US FDA approves Bristol Myers` schizophrenia drug
27 Sep 2024 //
REUTERS
Macleods Pharms Generic Trospium Chloride Receives Approval in US
18 Jun 2024 //
FDA
Enforcement Report - Week of December 13, 2023
13 Dec 2023 //
FDA
Amici`s Generic Trospium Chloride Receives Approval in the U.S.
16 Feb 2022 //
FDA
Granules Pharm`s Generic Trospium Chloride Receives Approval In US
24 Apr 2020 //
FDA
Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug Devel...
28 Jun 2019 //
BIOSPACE
Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug
28 Jun 2019 //
BIOSPACE
Quest for safe muscarinic receptor agonists to tackle disaster prone CNS field
04 Jun 2019 //
ENDPTS
Karuna Pharms to Present Results of KarXT Phase 1 Study at ACNPP
11 Dec 2018 //
BUSINESSWIRE
Daily Brief: Karuna raises $42m for novel CNS approach
02 Aug 2018 //
PM LIVE
Heritage Pharms Receive FDA Nod For Trospium Chloride
30 Aug 2016 //
FDA
Invagen Pharms ANDA Trospium Chloride Receives FDA Nod
24 Aug 2016 //
FDA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.